Gillian McGovern, Associate Editor

The approval is for those with metastatic disease or in whom surgical resection is likely to result in severe morbidity, have no satisfactory alternative treatments, or have progressed following treatment.

In patients with CKD, there were negative associations between the sodium cotransporter (NCC) and its phosphorylation (pNCC) in urinary extracellular vesicles (uEVs), but further research is needed to confirm these findings in a larger cohort.

The prevalence of hepatitis D virus (HDV) antibody positivity was about 0.24% in patients with chronic hepatitis B virus (HBV).

The future holds the promise of earlier diagnosis, more targeted therapies, and personalized neurological care, said speaker William D. Freeman, MD, FAAN.

Huntington disease (HD) has no curative treatments, therefore, there is a great need for therapies that can reduce or slow the progression of symptoms.

Numerical differences were observed as early as Month 1.

Small changes in blood pressure and pulse were shown in patients of all ages, and the authors suggested that these are monitored carefully in patients being treated for ADHD.

Advanced practice provider (APP) care models allow for health systems to better individualize care for patients, effectively meeting their needs.

Tirzepatide-treated patients with chronic kidney disease (CKD), obesity, and heart failure with preserved ejection fraction (HFpEF) had improved renal function both by cystatin C and creatinine.

Beth A. Malow, MD, MS, FAAN, said that pharmacists and health care professionals are at the frontlines of collaborating and raising awareness of climate change’s impacts.

Malow also emphasized the importance of staying educated on the potential neurological risks that may occur as a result of climate change.

The poll also showed that social media and general media coverage influenced about 33% of participants to not get vaccinated.

Among the 9 surface disinfectants studied, only 2 demonstrated a reduction in viral titer below the limit of detection.

This action makes inebilizumab the first and only FDA-approved treatment for adults with immunoglobulin G4-related disease (IgG4-RD).

No manufacturing or safety issues were identified, but the FDA stated the new drug application did not demonstrate efficacy in adequate and well-controlled studies.

The registry data showed that cardiac magnetic resonance (CMR) was obtained in more clinically complex patients with recurrent pericarditis.

The antibody-drug conjugate is currently undergoing evaluation in a phase 1 trial that enrolled patients with pancreatic cancer and squamous non-small cell lung cancer (NSCLC).

Currently, BEAM-302 is undergoing a phase 1/2 clinical trial to evaluate its efficacy in patients with alpha-1 antitrypsin deficiency (AATD) who have lung disease and liver disease.

Approval of durvalumab is in combination with gemcitabine and cisplatin as neoadjuvant treatment for adults with muscle invasive bladder cancer.

In certain patients with chronic kidney disease (CKD), peritoneal dialysis maintained hemodynamic stability, optimal nutritional status, reduced hospitalization, and lowered diuretics reliance.

At 12 and 24 months, there were 56.9% and 73.5% reductions in food-specific immunoglobulin E (IgE).

About 59.2% of patients with tardive dyskinesia (TD) who completed the 48-week trial achieved remission.

The hepatitis B core-related antigen (HBcrAg) rapid diagnostic test was more timely and showed a stronger sensitivity and specificity compared with other testing methods.

Gepotidacin is indicated for female patients who are at least 12 years of age and weigh at least 40 kg with uncomplicated urinary tract infections (uUTIs) caused by certain microorganisms.

A district leader at CVS Health emphasizes that patients should get tested, be up to date with immunizations, and staying home and reach out to health care professionals when experiencing symptoms.

Helping patients adhere to their medications to manage their chronic kidney disease (CKD) and comorbidities is one of the key areas pharmacists should prioritize.

Megan May, PharmD, BCOP, FHOPA, FAPO, discusses lurbinectedin and tarlatamab and what ongoing research in the small cell lung cancer (SCLC) space entails.

After decades without improvements, an expert with Baptist Health described the small cell lung cancer (SCLC) space as “exciting” following multiple innovations in the past few years.

Vutrisiran becomes the first and only therapeutic FDA-approved to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.

Approximately 74% of patients with chronic rhinosinusitis with nasal polyps receiving depemokimab across 2 trials did not need additional intervention.